Fig. 7
From: l-Carnitine ameliorates congenital myopathy in a tropomyosin 3 de novo mutation transgenic zebrafish
Analysis and interpretation the embryos of TPM3(E151A) and TPM3(E151G) transgenic fish with ingenuity pathway analysis. a List canonical signaling pathways and metabolic pathways affected by the TPM3(E151A), TPM3(E151G) and l-carnitine treated TPM3(E151G) by IPA analysis presented as hierarchical clustering. b List the upstream molecules related to the changing molecules in the TPM3(E151A), TPM3(E151G) and l-carnitine treated TPM3(E151G), and predict whether they are activated or inhibited based on the research literature presented as hierarchical clustering. c List of various analytical diseases and biological functions dysregulated by TPM3(E151A), TPM3(E151G) and l-carnitine treated TPM3(E151G) presented as hierarchical clustering. d Fatty acid metabolism is downregulated in TPM3(E151G) (left) and upregulated by l-carnitine treatment in TPM3(E151G) (right). The genes differential expressed are shown in red or blue indicated up-regulated or downregulated respectively. The blue or orange color in the center indicated fatty acid metabolism are downregulated or upregulated respectively